In Brief: Merck Zocor
Executive Summary
Merck Zocor: Liver function testing for patients on simvastatin now recommended at start of therapy and periodically (such as semi-annually) for first year of therapy. FDA approved the revised recommendations May 23. Bristol-Myers Squibb received clearance in April to remove the recommendation in labeling for Pravachol for testing at six weeks and for semi-annual testing in patients with normal results at 12 weeks ("The Pink Sheet" April 28, In Brief)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth